Normosang (Human Hemin)

Human hemin provides an external source of heme that binds to the regulatory site of aminolevulinic acid synthase (ALAS1), the first enzyme in the hepatic heme biosynthetic pathway. This feedback inhibition reduces the synthesis of aminolevulinic acid and porphobilinogen, the precursors that accumulate during porphyria attacks, thereby decreasing the biochemical trigger of symptoms.

The dosing regimen for Normosang is individualized by the treating physician based on the severity of the acute porphyria episode, patient weight, and clinical response. The prescriber determines the amount, frequency, and duration of intravenous infusion, and adjustments are made according to laboratory monitoring and symptom resolution.

Safety data for human hemin in pregnant or lactating women are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk, and it must be decided by the healthcare provider after careful assessment.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

The primary alternative to human hemin is glucose‑infused heme precursors such as heme arginate, which also supplies exogenous heme but differs in formulation and regulatory status. Normosang, as a lyophilized human hemin product, offers a standardized EU‑approved preparation with a well‑characterized safety profile, while other products may vary in source and stability.

Normosang must be stored refrigerated at 2–8 °C in its original packaging to protect it from light and moisture. The lyophilized powder should not be frozen or shaken. Prior to use, it is reconstituted with the appropriate diluent under aseptic conditions, and the solution should be administered promptly.

Normosang is supplied as a lyophilized powder for solution for injection and is administered intravenously. After reconstitution with a compatible sterile diluent, the solution is infused over a period determined by the prescriber, typically ranging from 30 minutes to several hours, under close medical supervision to monitor for infusion‑related reactions.

The most serious adverse events linked to Normosang include severe allergic reactions such as anaphylaxis, hemolysis in patients with glucose‑6‑phosphate dehydrogenase deficiency, acute renal failure, and coagulopathy. Prompt recognition and immediate medical intervention are essential if any of these rare but life‑threatening reactions occur during or after infusion.

Normosang is contraindicated in individuals with known hypersensitivity to human hemin or any of its excipients, and it should be avoided in patients with confirmed G6PD deficiency due to the risk of hemolysis. Caution is also advised for patients with severe hepatic or renal impairment, and the drug should not be used without medical supervision in these populations.